Literature DB >> 31413097

EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.

Sebastian Stasik1, Jan M Middeke1, Michael Kramer1, Christoph Röllig1, Alwin Krämer2, Sebastian Scholl3, Andreas Hochhaus3, Martina Crysandt4, Tim H Brümmendorf4, Ralph Naumann5, Björn Steffen6, Volker Kunzmann7, Hermann Einsele7, Markus Schaich8, Andreas Burchert9, Andreas Neubauer9, Kerstin Schäfer-Eckart10, Christoph Schliemann11, Stefan Krause12, Regina Herbst13, Mathias Hänel13, Norbert Frickhofen14, Richard Noppeney15, Ulrich Kaiser16, Claudia D Baldus17, Martin Kaufmann18, Zdenek Rácil19, Uwe Platzbecker20, Wolfgang E Berdel11, Jiri Mayer19, Hubert Serve6, Carsten Müller-Tidow2, Gerhard Ehninger1, Martin Bornhäuser1, Johannes Schetelig1,21, Christian Thiede22.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31413097      PMCID： PMC7193486          DOI： 10.3324/haematol.2019.222323

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.

Authors:  E Gillespie
Journal:  Biochem Pharmacol       Date:  1988-07-15       Impact factor: 5.858

2.  The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis.

Authors:  M Ahluwalia; L Butcher; H Donovan; C Killick-Cole; P M Jones; J D Erusalimsky
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

3.  Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.

Authors:  E M Mazur; A G Rosmarin; P A Sohl; J L Newton; A Narendran
Journal:  Blood       Date:  1992-04-15       Impact factor: 22.113

4.  Structural and functional comparison of the genes for human platelet factor 4 and PF4alt.

Authors:  R Eisman; S Surrey; B Ramachandran; E Schwartz; M Poncz
Journal:  Blood       Date:  1990-07-15       Impact factor: 22.113

5.  The effects of anagrelide on human megakaryocytopoiesis.

Authors:  L A Solberg; A Tefferi; K J Oles; J S Tarach; R M Petitt; L A Forstrom; M N Silverstein
Journal:  Br J Haematol       Date:  1997-10       Impact factor: 6.998

6.  Role of tumor suppressor p53 in megakaryopoiesis and platelet function.

Authors:  Pani A Apostolidis; Donna S Woulfe; Massiel Chavez; William M Miller; Eleftherios T Papoutsakis
Journal:  Exp Hematol       Date:  2011-10-21       Impact factor: 3.084

7.  Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells.

Authors:  Sou Nakamura; Naoya Takayama; Shinji Hirata; Hideya Seo; Hiroshi Endo; Kiyosumi Ochi; Ken-ichi Fujita; Tomo Koike; Ken-ichi Harimoto; Takeaki Dohda; Akira Watanabe; Keisuke Okita; Nobuyasu Takahashi; Akira Sawaguchi; Shinya Yamanaka; Hiromitsu Nakauchi; Satoshi Nishimura; Koji Eto
Journal:  Cell Stem Cell       Date:  2014-02-13       Impact factor: 24.633

8.  Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production.

Authors:  Yukitaka Ito; Sou Nakamura; Naoshi Sugimoto; Tomohiro Shigemori; Yoshikazu Kato; Mikiko Ohno; Shinya Sakuma; Keitaro Ito; Hiroki Kumon; Hidenori Hirose; Haruki Okamoto; Masayuki Nogawa; Mio Iwasaki; Shunsuke Kihara; Kosuke Fujio; Takuya Matsumoto; Natsumi Higashi; Kazuya Hashimoto; Akira Sawaguchi; Ken-Ichi Harimoto; Masato Nakagawa; Takuya Yamamoto; Makoto Handa; Naohide Watanabe; Eiichiro Nishi; Fumihito Arai; Satoshi Nishimura; Koji Eto
Journal:  Cell       Date:  2018-07-12       Impact factor: 41.582

9.  Small Molecule Supplements Improve Cultured Megakaryocyte Polyploidization by Modulating Multiple Cell Cycle Regulators.

Authors:  Xiaojing Zou; Mingyi Qu; Fang Fang; Zeng Fan; Lin Chen; Wen Yue; Xiaoyan Xie; Xuetao Pei
Journal:  Biomed Res Int       Date:  2017-10-19       Impact factor: 3.411

10.  Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis.

Authors:  Lee Butcher; Maninder Ahluwalia; Tiit Örd; Jessica Johnston; Roger H Morris; Endre Kiss-Toth; Tõnis Örd; Jorge D Erusalimsky
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379
View more
  7 in total

1.  Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.

Authors:  Jing Yang; Ellen L Weisberg; Shuang Qi; Wei Ni; Husheng Mei; Zuowei Wang; Chengcheng Meng; Shengzhe Zhang; Mingqi Hou; Ziping Qi; Aoli Wang; Yunyun Jiang; Zongru Jiang; Tao Huang; Qingwang Liu; Robert S Magin; Laura Doherty; Wenchao Wang; Jing Liu; Sara J Buhrlage; Qingsong Liu; James D Griffin
Journal:  Leukemia       Date:  2022-01-17       Impact factor: 11.528

2.  Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.

Authors:  Sebastian Stasik; Jan-Niklas Eckardt; Michael Kramer; Christoph Röllig; Alwin Krämer; Sebastian Scholl; Andreas Hochhaus; Martina Crysandt; Tim H Brümmendorf; Ralph Naumann; Björn Steffen; Volker Kunzmann; Hermann Einsele; Markus Schaich; Andreas Burchert; Andreas Neubauer; Kerstin Schäfer-Eckart; Christoph Schliemann; Stefan Krause; Regina Herbst; Mathias Hänel; Norbert Frickhofen; Richard Noppeney; Ulrich Kaiser; Claudia D Baldus; Martin Kaufmann; Zdenek Rácil; Uwe Platzbecker; Wolfgang E Berdel; Jiri Mayer; Hubert Serve; Carsten Müller-Tidow; Gerhard Ehninger; Martin Bornhäuser; Johannes Schetelig; Jan M Middeke; Christian Thiede
Journal:  Blood Adv       Date:  2021-09-14

3.  Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.

Authors:  Xuejie Jiang; Ling Jiang; Jiaying Cheng; Fang Chen; Jinle Ni; Changxin Yin; Qiang Wang; Zhixiang Wang; Dan Fang; Zhengshan Yi; Guopan Yu; Qingxiu Zhong; Bing Z Carter; Fanyi Meng
Journal:  J Transl Med       Date:  2021-03-21       Impact factor: 5.531

Review 4.  In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge.

Authors:  Paulina Stefaniuk; Agnieszka Szymczyk; Monika Podhorecka
Journal:  J Clin Med       Date:  2022-07-23       Impact factor: 4.964

5.  Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.

Authors:  Maximilian Fleischmann; Sebastian Scholl; Jochen J Frietsch; Inken Hilgendorf; Karin Schrenk; Jakob Hammersen; Florian Prims; Christian Thiede; Andreas Hochhaus; Ulf Schnetzke
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-31       Impact factor: 4.322

Review 6.  Chromosomal Instability in Acute Myeloid Leukemia.

Authors:  Mateus de Oliveira Lisboa; Paulo Roberto Slud Brofman; Ana Teresa Schmid-Braz; Aline Rangel-Pozzo; Sabine Mai
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

7.  Disruption of YY1-EZH2 Interaction Using Synthetic Peptides Inhibits Breast Cancer Development.

Authors:  Cheng Yi; Guangyue Li; Wenmeng Wang; Yixuan Sun; Yueling Zhang; Chen Zhong; Daniel B Stovall; Dangdang Li; Jinming Shi; Guangchao Sui
Journal:  Cancers (Basel)       Date:  2021-05-16       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.